# Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT04958434** · PHASE1 · TERMINATED · sponsor: **Suzhou Transcenta Therapeutics Co., Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Locally Advanced or Metastatic Cancers
- Metastatic Human Papillomavirus-Related Malignant Neoplasm

## Interventions

- **DRUG:** TST005

## Key facts

- **NCT ID:** NCT04958434
- **Lead sponsor:** Suzhou Transcenta Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-11
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Corporate Decision
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04958434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04958434, "Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04958434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*